Investigating the Bioavailability of Broccoli Extract Supplements

Part of paid clinical trials in Corvallis, Oregon.

Sponsor
Oregon State University
Study ID
NCT07564674
Status
Recruiting
Apply to this trial

Conditions

  • Diet, Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Avmacol Extra Strength with coating - 1 tablet — DIETARY_SUPPLEMENT
    Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
  • Avmacol chewable wafer - 2 tablets — DIETARY_SUPPLEMENT
    Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)
  • Avmacol Extra Strength with coating - 2 tablets — DIETARY_SUPPLEMENT
    Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Study Details

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. Participants will: * consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg) * complete 3 separate 24 hour study cycles * submit blood and urine samples for 24 hours * follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Key Dates

First listed
May 4, 2026
Start date
Aug 4, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2028

Study Design

Enrollment
12 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: 35 mg glucoraphanin
    Participants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating.
  • Active Comparator: 60 mg glucoraphanin
    Participants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each)
  • Active Comparator: 70 mg glucoraphanin
    Participants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each)

Primary Outcome Measure

Urine sulforaphane [ Time Frame: 0, 2, 4, 8, and 24 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon State UniversityCorvallisOregon97331
Sandra Uesugi, RN, BSN, MS
[email protected]
541-737-3594
Emily Ho, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Corvallis, OR

By research site
Oregon State University· Corvallis, OR

Related Studies